FDA Approves ORLADEYO® 150 mg Oral Pellets for Hereditary Angioedema in Adults and Adolescents

The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for an oral pellet formulation of once-daily ORLADEYO® (berotralstat). This new 150 mg pellet formulation provides an alternative administration option for adults and adolescents aged 12 years and older with hereditary angioedema (HAE) who may have difficulty swallowing capsules, offering more personalized treatment choice.